Erica Stringer-Reasor
Hematology & Oncology · Birmingham, ALNPI 1467629006
Payments from drug & device makers
Across 606 payments — averaging $29,881 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12.2M
- Pfizer$3.3M
- Seagen Inc.$1.6M
- Merck$492K
- Regeneron$135K
- Eli Lilly$101K
- plus $272K from 15 others
Across 4 payments — averaging $1335.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
- Novartis$870
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 126 | $12,198,532 |
| Pfizer | 113 | $3,315,956 |
| Seagen Inc. | 166 | $1,592,368 |
| Merck | 30 | $492,258 |
| Regeneron | 12 | $135,229 |
| Eli Lilly | 16 | $100,858 |
| Tesaro, Inc. | 6 | $83,345 |
| Jazz Pharmaceuticals Inc. | 9 | $74,402 |
| Novartis | 17 | $43,680 |
| Lilly USA, LLC | 54 | $22,972 |
| AstraZeneca | 20 | $16,985 |
| Genentech, Inc. | 6 | $15,350 |
| Mylan Institutional Inc. | 9 | $4,520 |
| Gilead | 10 | $3,766 |
| Daiichi Sankyo Inc. | 4 | $3,738 |
| Tersera Therapeutics LLC | 1 | $2,085 |
| Immunomedics, Inc. | 1 | $1,300 |
| Puma Biotechnology, Inc. | 1 | $96 |
| Amgen | 3 | $69 |
| Stemline Therapeutics Inc. | 1 | $62 |
| AbbVie | 1 | $18 |
How this compares
$18,107,591 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Birmingham
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
- Susan BalBirmingham$11.3M
- Pankit VachhaniBirmingham$7.9M
- Mehmet AkceBirmingham$5.4M
- Mayur NarkhedeBirmingham$4.9M
- Christos VaklavasBirmingham$4.9M
- Lisle NabellBirmingham$3.3M
- Omer JamyBirmingham$2.7M
- Francisco VizcarrondoBirmingham$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.